Search

Close
Research
Home > Research > Faculty
Research

HAN Yonglong  

  • Doctoral Supervisor, Chief Pharmacist
  • Department: Pharmacy
  • Research Area: Pharmacology, Clinical Pharmacy
  • Research Interests: Pharmacokinetics, Antitumor Pharmacology of Traditional Chinese Medicine
  • Contact: yonglongh@sjtu.edu.cn
Biography Positions Publications Research Projects Patents Others
  • PhD from Shanghai University of Traditional Chinese Medicine, 2010
  • MS from Heilongjiang University of Chinese Medicine, 2007
  • BE from China Pharmaceutical University, 1997
  • Deputy Director, Department of Pharmacy, Shanghai Sixth People's Hospital
  • Vice Chairman, Specialty Committee of Chinese Medicine Dispensing of World Federation of Chinese Medicine Societies 
  • Vice Chairman, Pharmaceutical Specialized Committee of Shanghai Pudong New Area Medical Association
  1. Meng Z, Chen J, Xu L, Xiao X, Zong L, Han Y*, Jiang B*. Study on Cytochrome P450 Metabolic Profile of Paclitaxel on Rats using QTOF-MS. Curr Drug Metab, 2024,25(5):330-339. doi: 10.2174/0113892002308509240711100502. 
  2. Xue XC, Zhou YY, Xu LY, Wei LY, Hu YJ, Yang J, Zhang XQ, Wang MY, Han YL*, Chen JJ*. Tongguanteng injection exerts anti-osteosarcoma effects through the ER stress-associated IRE1/CHOP pathway. BMC Complement Med Ther, 2024,24(1):400. doi: 10.1186/s12906-024-04689-7.
  3. Hu J, Hu Y, Xu L, Chen J, Shi M, Wu W, Yang J*, Han Y*. P-glycoprotein-mediated herb-drug interaction evaluation between Tenacissoside G and paclitaxel. Biomed Chromatogr, 2024,38(10):e5984.  doi: 10.1002/bmc.5984.
  4. Wei L, Meng J, Xiang D, Yang Q, Zhou Y, Xu L, Chen J, Han Y. The Pan-Cancer Analysis Uncovers the Prognostic and Immunotherapeutic Significance of CD19 as an Immune Marker in Tumor. Int J Gen Med, 2024,17:2593-2612. doi: 10.2147/IJGM.S459914.
  5. Wei L, Meng J, Xiang D, Yang Q, Zhou Y, Xu L, Wang M, Chen J*, Han Y*. Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma. BMC Complement Med Ther, 2024,24(1):67. doi: 10.1186/s12906-024-04354-z.
  6. Kong QW, Yang J, Li D, Ding YW, Hu YJ, Xue XC, Shi MZ, Jiang B, Zhou YY, Zhang M, Hu JD, Guo C, Chen JJ*, Han YL*. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo. J Ethnopharmacol, 2023,300:115728. doi: 10.1016/j.jep.2022.115728.
  7. Zhou L#, Han Y#, Yang Q, Xin B, Chi M, Huo Y, Guo C, Sun X. Scutellarin attenuates doxorubicin-induced oxidative stress, DNA damage, mitochondrial dysfunction, apoptosis and autophagy in H9c2 cells, cardiac fibroblasts and HUVECs. Toxicol In Vitro, 2022,82:105366. doi: 10.1016/j.tiv.2022.105366.
  8. Chen J, Zhang X, Xiao X, Ding Y, Zhang W, Shi M, Yang J, Liu Y*, Han Y*. Xiao-Ai-Ping Injection Enhances Effect of Paclitaxel to Suppress Breast Cancer Proliferation and Metastasis via Activating Transcription Factor 3. Integr Cancer Ther, 2020,19:1534735420906463. doi: 10.1177/1534735420906463.
  9. Zhang XQ, Ding YW, Chen JJ, Xiao X, Zhang W, Zhou L, Kong QW, Shi MZ, Yang J, Jiang B, Guo C*, Han YL*. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules. J Ethnopharmacol, 2020,261:113067. doi: 10.1016/j.jep.2020.113067. 
  10. Shi MZ, Xing TY, Chen JJ, Jiang B, Xiao X, Yang J, Zhu J, Guo C, Hu JD*, Han YL*. Effect of Xiao-Ai-Ping injection on paclitaxel pharmacokinetics in rats by LC-MS/MS method. J Pharm Biomed Anal, 2019,174:728-733. doi: 10.1016/j.jpba.2019.07.003.
  • 01/01/2025-12/31/2028
    National Natural Science Foundation of China, ¥480,000, 82474124
    Research on anti-ovarian cancer effect and mechanism of Tenacissimol A via LOXL2-mediated cuproptosis
    Role: Project leader
  • 12/01/2021-11/30/2024
    Science and Technology Project of Shanghai Pudong New Area Health Commission, ¥1,000,000, PW2021E-03 
    Systematic evaluation and mechanism study on chemotherapeutic synergistic effect and toxicity reduction of Tongguanteng injection in non-small cell lung cancer
    Role: Project leader
  • 07/01/2020-06/30/2023
    Shanghai Natural Science Foundation, ¥200,000, 20ZR1442400
    Study on the mechanism of Tenacigenin derivatives from Marsdenia tenacissima enhancing anti-ovarian cancer effect of paclitaxel based on PXR/MDR1/P-gp pathway
    Role: Project leader
  • 01/01/2018-12/31/2021
    National Natural Science Foundation of China, ¥550,000, 81773949
    Mechanism of Xiaoaiping injection enhancing the effect of paclitaxel on ovarian cancer by regulation of PXR/CAR
    Role: Project leader
  1. [Yonglong Han, Junjun Chen, Jiao Yang, Lingyan Xu, Meizhi Shi, Bo Jiang, Xiaochuan Xue, Yujie Hu, Lanyi Wei, Juan Zhao, Xinyun Han] (2022), “Application of Marsdenia tenacissima extract in anti-tumor therapy”, CN202211477627.7
  2. [Yonglong Han, Mengyue Wang, Xiaobo Li, Junjun Chen, Yangyun Zhou, Kezhi Zhang, Ziwei Wu, Qinfang Zhu, Zhaoyang Meng, Jingjing Meng, Danfeng Xiang, Xinyun Han] (2022), “High-purity preparation method of Antitumor tenacissimol”, CN202211546870.X
  • 2/8, Shanghai Chinese Integrative Medicine Science and Technology Award, First Prize, 2014
  • Research on Metabolic Drug-Drug Interactions of Commonly Used Traditional Chinese Medicines and the Active Ingredients,
  • Shanghai Association of Chinese Integrative Medicine 

Copyright © 2024, All Rights Reserved.